David John Lewis

Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities

Therapeutic Innovation & Regulatory Science

Dr. Lewis joined Novartis in March 2007 following 20 years’ pharmacovigilance at GSK and then at Shire. He was EU QPPV at Novartis Pharma AG from April 2009 then Global Head of Pharmacovigilance Systems & Data Management and was appointed Global Head of Pharmacovigilance in February 2011. Dr. Lewis has worked in country affiliates and in a variety of global safety & risk management functions with both investigational & marketed products, as well as in roles involving systems and processes. Dr. Lewis is the author of papers on the safety of medicines as well as research papers on neuropharmacology.